Diagnosis based on molecular changes
GynEC®-DX detects the molecular changes that precede the morphological alterations associated with endometrial cancer.
Detection by real-time PCR (qPCR)
GynEC®-DX uses the real-time PCR (qPCR) technology.
This technique requires the extraction of ribonucleic acids (RNA) from the aspirated sample and the synthesis of complementary DNA (cDNA).
Subsequently, the expression levels of five biomarkers are quantified by qPCR in relation to a reference gene. From these data, the GynEC®-DX decision algorithm generates a value indicative of the absence or presence of cancer.
GynEC®-DX is a non-invasive, rapid and reliable test that does not depend on the main variability factors of tests based on the histological classification: time, sample location and interpretation.
Time: GynEC®-DX offers an early diagnosis as it does not depend on morphological alterations at the cellular level, but on gene expression changes that always precede morphological changes.
Sample location: GynEC®-DX does not depend on how the sampling was directed, since it is based on an exudate representative of the entire endometrial epithelium.
Interpretation: GynEC®-DX does not depend on the variability in interpretation by the clinician , but on the result of a mathematical algorithm that has been scientifically validated to rule out the diagnosis of endometrial cancer.